Newsfeeds Archive - Spark Newswire

1 minute read

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?

June 9, 2:29 PM

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

ACLS

1 minute read

This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

By Avi Kapoor

June 7, 9:30 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

BBCP

4 minute read

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Avi Kapoor

June 6, 1:39 PM

Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday’s session after the company reported worse-than-expected quarterly…

AEMD

1 minute read

Halozyme Therapeutics +13% On Thursday: What’s Going On?

By Nabaparna Bhattacharya

June 6, 12:34 PM

Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for its drug delivery platform.

HALO

2 minute read

J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday

By Avi Kapoor

June 6, 10:44 AM

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of The…

CART

3 minute read

Analyst Ratings

A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts

By Benzinga Insights

June 4, 8:00 AM

8 analysts have shared their evaluations of Halozyme Therapeutics (NASDAQ:HALO) during the recent three months, expressing a mix…

HALO

1 minute read

News

Halozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated with ENHANZE (Halozyme’s Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024

By Benzinga Newsdesk

May 21, 7:55 AM

Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous

HALO